# **CMAJ-JAMC**

#### **EDITORIAL • RÉDACTION**

Editor-in-Chief • Rédacteur en chef John Hoey, MD (hoeyj@cma.ca)

#### Associate Editors • Rédacteurs associés

Tom Elmslie, MD, MSc Ken Flegel, MD, MSc K.S. Joseph, MD, PhD Anita Palepu, MD, MPH

James Hanley, PhD (Biostatistics • Biostatistique)

#### Editorial Fellow • Boursière en rédaction médicale Caralee E. Caplan, MD (caplac@cma.ca)

Managing Editor • Rédactrice administrative

## Jennifer Douglas (douglj@cma.ca)

News and Features Editor Rédacteur, informations générales Patrick Sullivan (sullip@cma.ca)

#### Editor, The Left Atrium Rédactrice, De l'oreille gauche

Anne Marie Todkill (todkia@cma.ca)

#### Editors • Rédactrices

Glenda Proctor (proctg@cma.ca) Kate Schissler (schisk@cma.ca) Barbara Sibbald (sibbab@cma.ca)

#### Assistant Editors • Rédacteurs adjoints

Jennifer Raiche (raichj@cma.ca) Steven Wharry (wharrs@cma.ca)

Editorial Administrator • Administratrice de rédaction Carole Corkery (corkec@cma.ca)

#### Manuscript Coordinator • Coordonnatrice des manuscrits Sylvie Urie (uries@cma.ca)

#### Editorial Assistants • Assistantes à la rédaction

Wilma Fatica (faticw@cma.ca) Zrinka Mamic (mamicz@cma.ca)

#### Translation Coordinator Coordonnatrice de la traduction

Coordonnatrice de la traduction Marie Saumure

### Contributing Editors • Rédactrices invitées

Gloria Baker; C.J. Brown, ELS; Charlotte Gray; Peggy Robinson, ELS

#### Editorial Board • Conseil de rédaction

Nicholas R. Anthonisen, MD, PhD (Winnipeg) Paul W. Armstrong, MD (Edmonton) Neil R. Cashman, MD (Toronto) Hugues Cormier, MD, MPH (Montréal) Raisa B. Deber, PhD (Toronto) C.I. de Gara, MB, MS (Edmonton) David H. Feeny, PhD (Edmonton) Antoine M. Hakim, MD, PhD (Ottawa) Judith G. Hall, MD (Vancouver) Carol P. Herbert, MD (Vancouver) Neill Iscoe, MD, CM, MSc (Toronto) Harriet L. MacMillan, MD, MSc (Hamilton) Allison J. McGeer, MD (Toronto) Olli S. Miettinen, MD, PhD (Montréal) C. David Naylor, MD, DPhil (Toronto) Susan Phillips, MD (Kingston) Louise Pilote, MD, MPH, PhD (Montréal) Martin T. Schechter, MD, PhD (Vancouver) Martin F. Shapiro, MD, PhD (Los Angeles) Richard Smith, MB, ChB (British Medical Journal, London, England)

All editorial matter in *CMAI* represents the opinions of the authors and not necessarily those of the Canadian Medical Association (CMA). The CMA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CMAJ* including editorials, studies, reports, letters and advertisements.

C. Peter Warren, MB (Winnipeg)

Tous les articles à caractère éditorial dans le *JAMC* représentent les opinions de leurs auteurs et n'engagent pas l'Association médicale canadienne (AMC). L'AMC décline toute responsabilité civile ou autre quant à toute erreur ou omission ou à l'usage de tout conseil ou information figurant dans le *JAMC* et les éditoriaux, études, rapports, lettres et publicités y paraissant.

# Editor's preface

Français à la page suivante



# New variant CJD and the blood supply: Canadian Blood Services reacts

ast September we urged Canadian ✓ blood authorities to address the problem of possible transmission of new variant Creutzfeldt-Jakob disease (nvCJD) through the blood supply.1 We take some small measure of satisfaction in the fact that Canadian Blood Services has finally established an advisory panel to come to terms with this issue.2 The question is whether any Canadian blood donors who travelled to England or France during the 1980s unknowingly contracted nvCJD through its presumed vector, beef and beef products contaminated with bovine spongiform encephalopathy. The related question of whether nvCJD can be transmitted through the blood supply is still unresolved, although evidence from animal experiments suggests that this possibility cannot be discounted.

Canadian Blood Services estimates that 22% of Canadian donors travelled to the UK during the risk period and 15% to France. Most of these donors give blood frequently. Clearly, deferring their donations would seriously deplete blood supplies and necessitate either a huge increase in donations from other Canadians or the purchase of blood products on the open market, with all of the risks and uncertainties that this would entail. The advisory panel is expected to make its recommendations this month.

New cases of nvCJD continue to surface in the UK. As of Mar. 31, 1999, there were 38 confirmed and 2 probable cases. The median age of onset for the cases reported to the end of 1998 was 28 years; the median age at death was 29 years. (The median age at death for sporadic CJD is 65 years.) The median delay beween onset of symptoms

and diagnosis is 15 months. The interval between exposure to the causative agent and confirmation of diagnosis is presumably longer and is the dangerous window for the blood supply. Although the annual number of cases has risen from 3 in 1995 to 16 in 1998, there is no evidence of a real increase in incidence. Some of the observed increase may simply be an artifact of better surveillance.

The diagnosis of nvCJD is extremely difficult to make in the early stages. Dr. R.G. Will of the National Creutzfeldt-Jakob Disease Surveillance Unit in Edinburgh advised neurologists in the UK that the presentation is predominantly psychiatric, involving anxiety, depression, withdrawal and progressive behavioural change: "Nearly all these patients were referred to a psychiatrist early in the clinical course. ... After a period of weeks or months [they experienced] a cerebellar syndrome with gait and limb ataxia. Forgetfulness and memory disturbance develop[ed], often late in the clinical course but progress[ed] with the development of severe cognitive impairment and a state of akinetic mutism in the majority of cases."3

Close to 600 000 Canadians travel to the UK each year, and hence millions of visits were made during the risk period. Although there have been no confirmed cases of nvCJD in North America, or in fact anywhere outside the UK or France (where a single case has been reported), Canadian physicians should remain alert to this diagnosis.

#### References

- Hoey J, Giulivi A, Todkill AM. New variant Creuzfeldt–Jakob disease and the blood supply: Is it time to face the music? CMAJ 1998;159(6): 669-70.
- Canadian Blood Services. CBS launches consultation regarding deferral of blood donors [news release]. Ottawa: May 5, 1999. Available: www.bloodservices.ca/english/news/nr/1990505 a.html
- Will RG. Letter to neurologists, Mar. 21, 1996. Available: www.cjd.ed.ac.uk/letter.htm